BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020.

POXEL SA and Sumitomo Dainippon Pharma Co., Ltd announced positive topline results from TIMES 2, a Phase 3 trial evaluating Imeglimin in combination with approved hypoglycemic therapies, and as a monotherapy, for the treatment of type 2 diabetes in Japan.

InxMed Co., Ltd. announced that the Company has obtained IND clearance for IN10018, a proprietary focal adhesion kinase inhibitor, from China National Medical Products Administration to initiate Phase I clinical trial in patients with locally advanced or metastatic gastric cancer.

Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL). A patent covering the Active Pharmaceutical Ingredient (API), arfolitixorin hemisulfate, in Isofol’s drug candidate has been approved by the the Japanense Patent Office.

Hillrom (NYSE: HRC) today announced that its board of directors has nominated Felicia Norwood to stand for election as a director at the company’s Annual Meeting of Shareholders on February 25, 2020.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI).

Hutchison China MediTech Limited announces that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Priority Review status to the New Drug Application for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine tumors.

Vizient, Inc. praised the work of the House and Senate in approving year-end spending legislation that includes the Creating and Restoring Equal Access to Equivalent Samples Act.

Healthcare Trust, Inc. (Nasdaq: HTIA) (“HTI”) announced today that it intends to pay dividends on a quarterly basis on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) at an annualized rate of $1.84375 per share or $0.4609375 per share on a quarterly basis.

Dedicated to shaping the next frontier of surgery, Johnson & Johnsoni (NYSE: JNJ) today announced an agreement to acquire the remaining stake in Verb Surgical Inc. following a successful strategic collaboration with Verily, an Alphabet company.